Published by Coherent Market Insights
Posted on September 28, 2021
4 min readLast updated: February 1, 2026
The Sickle Cell Anemia Therapeutics market is growing due to increased prevalence and FDA approvals, with key players like Pfizer leading the way.
Sickle Cell Anemia Therapeutics Market (Forecast Period 2021-2028): The report provides a valuable source of insightful data for business strategists and competitive analysis of Sickle Cell Anemia Therapeutics Market. The study covers important knowledge that makes the analysis document a handy resource for managers, analysts, business consultants and different key individuals get ready-to-access and self-analyzed study in conjunction with graphs and tables to assist perceive market trends, drivers and market challenges.It also highlights the restraints and opportunities expected to influence the market’s growth during the said period. The study provides a holistic perspective on the market’s growth throughout the above mentioned forecast period in terms of revenue(in US$ Mn) and Volume (Thousand Units), across different geographies.
To Access the Sample Report Click Here: https://www.coherentmarketinsights.com/insight/request-sample/161
Note: *The Sample only consist of Table of Content (ToC), Research Framework of the actual report, and Research Methodology adopted for it.
Major Players In This Market Are: Bristol-Myers Squibb, GlycoMimetics, Pfizer,Anthera Pharmaceuticals Inc., GlycoMimetics, Inc., Eli Lilly, and Mast Therapeutics
Sickle cell anemia therapeutics include medication, blood transfusions, and sometimes a bone-marrow transplant. Sickle-cell diseases are types of blood disorders which are usually inherited genetically. Currently, hematopoietic stem cell transplant is the only curative therapy available for patients with sickle cell disease. However, hematopoietic stem cell transplant is a rigorous, time-consuming, potentially high-risk procedure; it is only used when the benefits of a cure outweigh the considerable risks of the procedure, and only when a suitable donor is available. One of the common types of sickle cell diseases is the sickle cell anemia.
Therefore, growth of the sickle cell anemia therapeutics market is attributed to the increasing prevalence of sickle cell anemia, especially in the United States. Sickle cell disease is among the most common genetic diseases in the U.S. According to the Centers for Disease Control and Prevention (CDC), sickle cell disease affects around 70,000 to 100,000 people in the U.S. However, the exact number of people living with sickle cell disease in the U.S. is unknown. Thus, with the increasing prevalence of sickle cell anemia, the demand for sickle cell anemia therapeutics is also increasing in this region.
For example, in November 2019, the Food and Drug Administration (FDA) granted accelerated approval to voxelotor (Oxbryta, Global Blood Therapeutics) for adults and pediatric patients 12 years of age and older with sickle cell disease. Moreover, November 2019, FDA approved crizanlizumab-tmca (ADAKVEO, Novartis) to reduce the frequency of vaso-occlusive crises (VOCs) in adults and pediatric patients aged 16 years and older with sickle cell disease. This in turn is expected to augment the growth of the sickle cell anemia therapeutics market in North America, especially in the U.S.
Sickle cell disease is common among people of Middle Eastern, African, and South Asian descent. Sickle cell anemia can have genotypic and phenotypic variants based on different mutations in hemoglobin genes. Sickle cell diseases, such as sickle cell anemia, are very common among Black or African Americans. According to the CDC, sickle cell disease occurs among about 1 out of every 365 Black or African-American births. Moreover, around 1 in 13 Black or African-American babies born with sickle cell trait. The increasing prevalence of the disease will increase the demand for prevention and treatment of sickle cell disease.
Buy This Premium Report Of Sickle Cell Anemia Therapeutics Market Report 2021 With Flat USD 2000 OFF @ https://www.coherentmarketinsights.com/promo/buynow/161
In this study, the years considered to estimate the market size of Sickle Cell Anemia Therapeutics are as follows:
History Year: 2017-2020
Base Year: 2020
Estimated Year: 2021
Forecast Year 2021 to 2028
The next part also sheds light on the gap between supply and consumption. Apart from the mentioned information, growth rate of Sickle Cell Anemia Therapeutics Market in 2028 is also explained. Additionally, type wise and application wise consumption tables and figures of Sickle Cell Anemia Therapeutics Market are also given.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
The post Sickle Cell Anemia Therapeutics Market Growth Rate, Overview, Price Analysis of Top Manufactures Profiles and Forecast 2028 appeared first on Gatorledger.
The article focuses on the growth and trends in the Sickle Cell Anemia Therapeutics market.
Major players include Bristol-Myers Squibb, Pfizer, and Eli Lilly.
Increasing prevalence of sickle cell anemia and FDA approvals are key drivers.
Explore more articles in the Research Reports category
